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Abstract
Background: Highly parallel analysis of gene expression has recently been used to identify gene sets or ‘signatures’ to
improve patient diagnosis and risk stratification. Once a signature is generated, traditional statistical testing is used to
evaluate its prognostic performance. However, due to the dimensionality of microarrays, this can lead to false interpretation
of these signatures.
Principal Findings: A method was developed to test batches of a user-specified number of randomly chosen signatures in
patient microarray datasets. The percentage of random generated signatures yielding prognostic value was assessed using
ROC analysis by calculating the area under the curve (AUC) in six public available cancer patient microarray datasets. We
found that a signature consisting of randomly selected genes has an average 10% chance of reaching significance when
assessed in a single dataset, but can range from 1% to ,40% depending on the dataset in question. Increasing the number
of validation datasets markedly reduces this number.
Conclusions: We have shown that the use of an arbitrary cut-off value for evaluation of signature significance is not suitable
for this type of research, but should be defined for each dataset separately. Our method can be used to establish and
evaluate signature performance of any derived gene signature in a dataset by comparing its performance to thousands of
randomly generated signatures. It will be of most interest for cases where few data are available and testing in multiple
datasets is limited.
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Introduction
In recent years, DNA microarray technology has been
increasingly used in oncology. It has provided insight into the
biological mechanisms underlying tumour formation and identi-
fied new therapy targets [1,2]. However, most studies performed
in this field identify gene sets, or so-called signatures, which can be
used to improve diagnosis and risk stratification [3,4,5,6]. These
signatures can be acquired through supervised analysis methods
[7]. Both patient microarray and clinical data are directly used to
find the genes that correlate with tumour type or patient outcome
[8,9,10,11,12]. Also biology-based signatures can be used for
patient prognosis, which are usually derived from in vitro
microarray data [2,13,14,15]. Though the performance of these
classifiers can be very high in the dataset studied, application of
these signatures in other datasets is often limited and data
reproduction is not straightforward [16]. Furthermore, signatures
identified in comparable studies show little overlap in gene content
[1,10,17,18,19,20]. Michiels et al. [4] showed that identified gene
lists were highly variable within one dataset and depended on the
patients included in the training set. Further, they demonstrated
that several published gene classifiers did not classify patients
better than by chance. They stress that validation is an important
issue in microarray research. Fan et al. [21] repeated and extended
these analyses 5 years later and made similar conclusions.
Moreover Boutros et al. [19] amongst other showed that the use
of different statistical procedures could identify multiple highly
prognostic signatures from one dataset [22,23]. An extensive
analysis of the effect of different statistics on ranked gene lists
showed large variability [24].
A major challenge with DNA microarray technology is to take
account of variability across a very large number of parameters
[1]. This variability arises from several sources: the biological
samples, hybridisation protocols, scanning, and image and
statistical analysis [7]. In a recent review, Dupuy et al. [1]
demonstrated that proper methodology in pre-processing and
statistical analysis is essential in these sorts of studies. They found
that a large subset of published microarray studies show flaws in
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genes and inadequate control of multiple testing is performed. The
issue of multiple testing is crucial, as microarrays monitor the
expression of thousands of genes, while the number of samples is
relatively small.
Statistical significance of the differences in gene expression
patterns for different patient groups or tumour types is often
determined with traditional statistical testing procedures, such as
the two-sample t-tests or Wilcoxon rank sum tests [1,7,20]. These
procedures are challenged with serious multiplicity and without
employment of a correction for multiple testing, the number of
false positives will be extremely high. Various methods have been
developed to overcome this problem of identifying differentially
expressed genes and are used to create gene signatures
[11,19,20,25].
More importantly multiple testing is often not considered in
evaluating the prognostic power of signatures. Once a signature is
created, its prognostic power is determined with traditional
survival statistics and standard cut-off values for significance. We
hypothesise that this can lead to high numbers of false prognostic
signatures when the number of evaluated datasets is limited.
Therefore we sought to develop a simple method to take into
account the high-dimensionality of microarrays in the phase of
evaluating signature prognosticity.
To quantify the problem of multiple testing we have developed
a method to test batches of random signatures in microarray
datasets. We show that the average chance that a random
signature produces a prognostic result in one dataset is
approximately 10% but can range from 1% to ,40%. Increasing
the number of datasets reduces this false positive rate significantly.
As a result of this high degree of variability amongst datasets, we
developed a method that can be used to determine an appropriate
threshold level of significance that must be reached for a given
signature. This is done by testing a set of randomly chosen
signatures along with the signature of interest within the dataset
under investigation.
Results
In order to assess the potential for identifying prognostic gene
signatures by chance alone in microarray based datasets a method
was developed to test the prognostic value of batches of randomly
generated signatures. Six different publicly available microarray
datasets with follow-up data were used (Table 1). These six
datasets differ in number of patients, number of measured genes,
number of reporters measured per gene, as well as platform and
type of cancer.
For each dataset separately 5 batches of 10,000 random
signatures were generated and tested. In each batch the number
of genes (UnigeneIDs) in a gene set was predefined. The number
of genes (UnigeneIDs) in the five batches were 10, 25, 50, 100 and
200 respectively. For example, the first batch included 10,000
random signatures, each consisting of ten genes. For each
signature a patient score was derived, defined as the average of
the expression of the genes in a signature (equation 1). Each
signature score was then tested for prognostic value by ROC
analysis and determination of the AUC. Figure 1A–F shows the
distribution of the AUCs for the first batch of 10,000 random
signatures for the different datasets.
To define a reasonable cut-off value for the AUC values, we first
searched for AUCs used in published gene signatures. However,
the majority of studies do not evaluate gene signatures using the
AUC. Most gene signatures are evaluated with Kaplan-Meier
survival curves and log-rank tests. Kaplan-Meier survival analyses
and ROC analyses are linked; a high AUC corresponds to a good
separation in distinct survival groups. To be able to define a cut-
off, we calculated the AUCs for the different gene sets as evaluated
in the review by Ntzani et al. [26]. The calculated AUCs as well as
additional information are provided in Supplementary File S1.
Based on these calculations we chose the cut-off values AUC#0.4
and $0.6.
In Figure 1G the percentages of signatures that passed the
criteria for the different batches of signatures are given. These
percentages range from 1% to ,40%, dependent on the dataset
and the number of genes in the signatures. Table 2 provides the
average, standard deviation as well as maximum and minimum
AUC for the analyses with the gene sets consisting of ten genes.
These data show that the larger the standard deviation, the higher
the chance that a randomly generated signature is considered
prognostic. Further, the maximum and minimum AUC show that
very high signature performances can be found at random.
Sampling 10,000 gene sets is a small number compared to the
total number of possible gene sets. In order to show that the
10,000 random gene sets are sufficient to estimate the AUC
distribution, we tested batches of 1,000,000 signatures consisting of
10 genes in the six datasets. The AUC distributions for this
permutation study were similar to the distributions for the batches
of 10,000 gene sets (Table 3).
From the differences between the six datasets (Table 1), it could
be that the number of patients, the number of genes (UnigeneIDs)
Table 1. Overview of the analysed patient microarray datasets.
Dataset Cancer type
Number of
patients with
survival data
Number of
UnigeneIDs
on array
Average number of
reporters measured
per UnigeneID Source
Miller Breast cancer 236 20,647 1.97 GEO accession GSE3494:
http://www.ncbi.nlm.nih.gov/projects/geo/
Wang Breast cancer 286 12,867 1.61 GEO accession GSE2034:
http://www.ncbi.nlm.nih.gov/projects/geo/
Van de Vijver Breast cancer 295 18,781 1.21 http://microarray-pubs.stanford.edu/wound_NKI/
Zhao Renal cancer 177 5,640 1.40 SMD:
http://smd.stanford.edu/
Beer Lung cancer 86 5,396 1.15 http://dot.ped.med.umich.edu:2000/ourimage/pub/Lung/index.html
Garber Lung cancer 24 4,936 1.15 SMD:
http://smd.stanford.edu/
doi:10.1371/journal.pone.0028320.t001
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probability that a randomly chosen signature is considered
prognostic. To further investigate the impact of these parameters,
the Miller dataset was used. To determine the influence of patient
number, the dataset was split in halves and in quarters. For these
partial datasets the same five batches of 10,000 random signatures
were tested. The influence of the number of genes was tested by
splitting the dataset in half, this time based on genes rather than
patients. Again, five batches of 10,000 random signatures were
tested. To investigate the influence of the number of reporters
measured per gene, again a set of five batches of 10,000 genes was
tested on the dataset, considering only genes with more than one
reporter. This was repeated, but for each gene only one reporter
measurement was considered. Of these parameters only patient
number influenced the false discovery rate. Results of the analysis
to determine the influence of the number of genes and the number
of reporters measured per gene are given in Supplementary File S1
and figures S1A and S1B.
Influence of patient numbers
It has already been reported in previous studies [26,27] that the
number of patients influences the false discovery rate. The Miller
dataset was split into two and four groups respectively to confirm
the importance of this factor. The same 5 batches of 10,000
random signatures that were tested on the whole dataset were
tested on these subgroups (Figure 2A). Indeed the number of
prognostic signatures increases dramatically when the size of the
patient group decreases. To characterize the relationship between
patient number and the probability that a randomly chosen
signature is considered prognostic, additional analyses were
performed for the batch of 10,000 runs with ten genes. The
dataset was split into three, five and ten groups respectively.
Figure 2B shows the distribution of the AUCs for the batch of
10,000 random signatures consisting of ten genes for the different
dataset sizes. It is clear that the smaller the dataset, the wider and
flatter the distribution becomes. Figure 2C presents the number of
prognostic signatures as a function of dataset size.
Effect of filtering
One of the parameters that could account for differences in the
number of prognostic signatures for a given dataset is filtering. To
briefly explore the influence of filtering, two simple filtering
methods were applied on the Miller dataset. After this filtering,
again five batches of 10,000 signatures were tested.
The first filtering procedure was to only consider reporters that
had no absent calls in the patients. This very stringent filtering
resulted in a reduction in number of reporters from ,45,000 to
,7,300 (approximately 5,000 unique UnigeneIDs). The second
filtering method, often used in microarray based studies, consists of
simply applying a threshold to the fold change. To show the effect
of this step on the number of false positives a twofold threshold was
applied. Only genes that show at least a two-fold change across the
patients are considered. This reduced the number of reporters
from ,45,000 to ,23,000.
The results for these analyses show that both filtering methods
have a different effect (Figure S1C). Fold change filtering did not
influence the probability that a randomly chosen signature is
considered prognostic; rather, it provides similar results to those of
non-filtered analysis. Filtering for absent reporters, on the other
hand, introduced a signature size dependency for the false positive
rate. A small signature size resulted in a false positive rate of
,10%, whereas large signatures had a false discovery rate of only
,0.5%. The average, however, stands at 5–6%, similar to the
non-filtering and fold change filtering analyses.
Signature testing procedure
To demonstrate that this random signature method can be used
with all sorts of signature evaluation methods, two additional
evaluation procedures were tested in the Miller dataset. In the
previous analyses the signature score was used as continuous
variable.
Here we selected 10,000 random samples of 10, 25, 50, 100 and
200 genes. In the first setup the signature score was used to median
dichotomize the patients. In the second setup these gene subsets
were in a K-nearest neighbor classification (KNN) combined with
leave-one-out-cross validation (LOOCV). Both procedures results
in patient classification into two groups, which were then coupled to
outcome and evaluated by the AUC. Similar AUC distributions are
obtained with these different signature evaluation procedures, exact
distributions characteristics differ slightly (Table 4). The numbers of
random gene sets passing the criteria are comparable (Figure S1D).
Evaluating signatures by random testing
To show that the random signature testing method is a valuable
tool in microarray based studies, several published gene signatures
Figure 1. Random signature AUC distribution in different published microarray datasets. Batches of 10,000 random signatures were
tested in six publicly available expression microarray datasets. Receiver-operator curves (ROC) were used to evaluate the signatures. The distribution
of the AUC for the different datasets for the batch of 10,000 random signatures consisting of ten genes are displayed ((A) Miller dataset, (B) Wang
dataset, (C) van de Vijver dataset, (D) Zhao dataset, (E) Beer dataset, (F) Garber dataset). The percentages of signatures that pass the criteria of
AUC#0.4 or AUC$0.6 for the 5 batches of 10,000 runs are shown in (G).
doi:10.1371/journal.pone.0028320.g001
Table 2. A batch of 10,000 random signatures of 10 genes was tested in the six datasets.
Dataset Average (± standard deviation) AUC Maximum AUC Minimum AUC
Miller 0.50560.054 0.692 0.312
Wang 0.47560.043 0.644 0.329
van de Vijver 0.49960.073 0.744 0.297
Zhao 0.47260.048 0.666 0.333
Beer 0.50260.073 0.753 0.249
Garber 0.53660.118 0.938 0.031
doi:10.1371/journal.pone.0028320.t002
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Dataset Average (± standard deviation) AUC Maximum AUC Minimum AUC
Miller 0.50360.044 0.688 0.290
Wang 0.47560.042 0.691 0.303
van de Vijver 0.51160.072 0.778 0.209
Zhao 0.47260.048 0.699 0.283
Beer 0.50360.073 0.831 0.196
Garber 0.53960.117 1.000 0.000
doi:10.1371/journal.pone.0028320.t003
Figure 2. Effect of dataset size on random signature AUC distribution. Percentages of signatures that pass the criteria of AUC#0.4 or
AUC$0.6 for the 5 batches of 10,000 runs for the Miller dataset, groups consisting of half the Miller dataset patients and groups with a quarter of the
Miller dataset patients (A). Distribution of the AUC for the different subdivisions of the Miller dataset, for the batch with 10,000 random signatures
consisting of ten genes (B). Relationship between size of the dataset and the false discovery rate in the Miller dataset (C).
doi:10.1371/journal.pone.0028320.g002
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a dataset is as follows (Figure 3). For the signature of interest the
AUC was calculated in the dataset, additionally the AUC
distribution for batches of random signatures with a similar size
as the signature of interest was computed. The signature AUC was
then compared to the random signature AUC distribution with a
Z-test to assess whether the signature of interest performed better
than could be expected by chance.
The Wound signature [13], ‘‘invasiveness gene signature’’ (IGS)
[10] and two early hypoxia signatures [15] are recently published
gene signatures. For the Wound and IGS signatures it was
previously shown that these signatures had high prognostic value
in different datasets and cancer types [10,13,28]. The two early
hypoxia signatures however, were only evaluated in one dataset
[15]. These signatures were evaluated in the three breast cancer
datasets [8,29,30] with the signature score (details are provided in
Supplementary File S1).
For the Miller dataset also Kaplan-Meier survival analyses were
performed, since the two early hypoxia signatures were previously
tested in this dataset. The results of Kaplan-Meier survival
analyses and the random signature testing are given in Table 5 and
Figure S3. From the Kaplan-Meier survival analyses all four
signatures seemed to have a high prognostic value (p-values log-
rank test ,0.05). However the random signature testing procedure
indicated that the two early hypoxia signatures did not perform
better than chance in that dataset. Testing the four signatures in
the other two breast cancer datasets indeed showed that the two
early hypoxia signatures did not have prognostic value (p-values
log-rank test .0.05). For the Wound and IGS signatures both
evaluation procedures indicated that the performance of these
signatures is high in the different datasets and that this is unlikely
due to chance.
Discussion
We assessed six patient microarray datasets spanning different
cancer types, numbers of patients and arrays to evaluate the effect
of false positives on gene signature evaluation. Different-sized
batches of 10,000 random signatures were tested in all datasets.
With the given threshold, the average chance that a randomly
generated signature was considered prognostic was approximately
10%, but ranged from 1% to ,40%.
Testing batches of random signatures in different datasets
revealed that the AUC distribution varied widely between
datasets. Choosing an arbitrary cut-off value for significance is
then clearly not suited for gene signature evaluation. Rather a
dataset-based cut-off value should be considered. The random
testing method we propose here can be applied to calculate the
level of AUC necessary to reach significance beyond random for a
given signature size in a given dataset.
Table 4. Batches of 1,000,000 random signatures of 10, 25, 50, 100 and 200 genes were tested in the Miller dataset, where three
different signature evaluation procedures were used.
Signature score Median dichotomized KNN with LOOCV
% UnigeneIDs in signature
Average AUC
(± standard deviation) [min - max]
Average AUC
(± standard deviation) [min - max]
Average AUC
(± standard deviation) [min - max]
10 0.50560.054 0.53560.045 0.55360.036
0.312–0.692 0.348–0.702 0.426–0.717
25 0.50760.054 0.53560.045 0.55860.033
0.313–0.692 0.338–0.690 0.412–0.697
50 0.50960.055 0.53860.045 0.56160.031
0.304–0.694 0.374–0.671 0.457–0.678
100 0.51360.053 0.54060.044 0.56260.030
0.319–0.682 0.352–0.679 0.435–0.689
200 0.51860.052 0.54360.043 0.56260.029
0.335–0.684 0.373–0.688 0.449–0.691
doi:10.1371/journal.pone.0028320.t004
Figure 3. Workflow signature testing procedure. A systematic
overview of the proposed signature testing procedure is depicted here.
First performance of the signature of interest is determined. A batch of
random gene sets with the same size as the signature is subsequently
tested. Signature performance is then compared to the AUC
distribution of the random gene sets with a Z-test to address whether
the signature performs better than random.
doi:10.1371/journal.pone.0028320.g003
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whether the performance of a certain signature could be due to
chance. A schematic overview is given in Figure 3. A batch of
random signatures withthe same size as the signature of interest can
be tested along with the original signature. The AUC distribution of
the random signatures can then be used to statistically test whether
the original signature performs better than random. An equivalent
permutation-based validation step was used by Boutros et al. [19] to
evaluate their signature; this step provided significant information
on the prognostic performance of the gene set.
We have shown that proper validation is absolutely essential in
gene signature research. This supports several previous studies, which
have argued that signature performance is often overestimated due to
improper validation in a large number of studies [1,26]. For several
analyses, the maximum and minimum AUC were also calculated.
We show that random signatures can have very high performances
(AUC.0.9), which further supports this observation.
A method to overcome this multiple testing problem is
validation in multiple independent datasets. We have shown that
testing random signatures in two datasets decreased the chance
that a random signature is called prognostic dramatically (Figure
S2). However it is not always possible to validate a gene signature
in multiple datasets. In oncology most microarray studies focus on
breast and lung cancer, for these sites there are a lot of public
datasets available that can be used for validation. Therefore this
technique is not primarily meant for these cancer types, but rather
for tumour types where only few data, in terms of the number of
samples and number of datasets, are available; for those cases this
technique would be valuable. By comparing the performance of
four published signatures in one patient microarray dataset with
Kaplan-Meier curves all signatures seemed to have prognostic
value. However, applying the random testing procedure in that
dataset already indicated that two out of four signatures did not
perform better than chance. Testing the four signatures in multiple
datasets indeed showed that these two signatures did not show
prognostic value in the other datasets.
From the analyses on all six datasets, several parameters could
influence the number of false positives. To assess the effect of these
variables, several parameters were manipulated in one of the
datasets. However, of the tested parameters, only patient number
influenced the false positive rate dramatically. The need for large
patient groups to obtain reliable results has already been
recognised in other studies. Ntzani et al. [26] evaluated 84
microarray studies and concluded that small studies often give
inflated, over-promising results. Zien et al. [27] assessed the
influence of the number of samples in a different way: a simulation
model was applied in which specificity and sensitivity were
measured depending on changes in sample size, technical and
biological variability. They showed that with small sample sizes,
sensitivity and specificity were highly dependent on the biological
and technical variance, whereas larger sample sizes led to quite
robust results that were less dependent on biological and technical
variance. Moreover Popovici et al. [23] tested the effect of training
set size on the performance of the trained marker in a validation
dataset. Overall signature performance improved in the validation
data and better concordance between training and testing results
was observed when training dataset size increased.
Testing batches of random generated gene sets in different gene
expression microarray datasets showed that the use of an arbitrary
cut-off value for evaluation of signature significance is not suitable.
Further it is important to use the same signature evaluation
procedure for the random gene sets as for the signature of interest,
since the AUC distribution can differ when using a different method.
Thresholds should be defined for single datasets separately in order
Table 5. Evaluating 4 published signatures with the random signature testing procedure in three breast cancer datasets.
Wound signature
Dataset p-value [log rank test] HR [95% CI] p-value [Wald test] AUC p-value [Z-test]
Miller 0.001 2.48 [1.40–4.41] 0.002 0.671 0.002
Wang 0.016 1.59 [1.08–2.36] 0.017 0.597 0.001
van de Vijver 7.27 10
29 4.15 [2.42–7.04] 7.71 10
28 0.688 0.018
IGS signature
Dataset p-value [log rank test] HR [95% CI] p-value [Wald test] AUC p-value [Z-test]
Miller 5.28 10
24 2.66 [1.49–4.78] 7.93 10
24 0.645 0.010
Wang 8.11 10
25 2.17 [1.45–3.25] 1.17 10
24 0.644 5.80 10
25
van de Vijver 2.16 10
26 3.12 [1.88–5.15] 6.35 10
26 0.668 0.038
Early 0%
Dataset p-value [log rank test] HR [95% CI] p-value [Wald test] AUC p-value [Z-test]
Miller 0.014 2.00 [1.13–3.53] 0.015 0.601 0.083
Wang 0.051 0.69 [0.47–1.02] 0.055 0.452 0.001
van de Vijver 0.786 1.06 [0.67–1.67] 0.785 0.508 0.162
Early 2%
Dataset p-value [log rank test] HR [95% CI] p-value [Wald test] AUC p-value [Z-test]
Miller 0.026 1.85 [1.06–3.22] 0.027 0.593 0.105
Wang 0.545 0.89 [0.61–1.32] 0.558 0.498 0.045
van de Vijver 0.321 1.25 [0.80–1.97] 0.321 0.549 0.418
doi:10.1371/journal.pone.0028320.t005
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to establish and evaluate signature performance of any derived gene
set within single or multiple datasets by comparing its performance
to the performance distribution of thousands of randomly generated
signatures. However itwillbe of most interestfor cases where limited
data is available.
Methods
Random signature testing
A method to test the prognostic value of random gene signatures
of a predefined size on a microarray dataset was developed in
Matlab (Matlab 7.1, The Mathworks, Natick, MA, USA). Unless
indicated otherwise, analyses were performed using this program.
The program creates a user-specified number of random gene sets,
consisting of a user-specified number of genes. For a given dataset
all genes on the respective microarray were used to create the
random signatures. This batch of random signatures was then
tested on a dataset by means of a signature score calculation.
Datasets
Patient microarray and clinical follow-up data were collated to
test the random gene sets. Datasets are publicly available in the
microarray databases Gene Expression Omnibus (GEO: http://
www.ncbi.nlm.nih.gov/projects/geo/) and Stanford Microarray
Database (SMD: http://genome-www.stanford.edu/microarray)
and elsewhere. Accessory clinical and follow-up data were also
given or provided by the authors on request. Table 1 provides an
overview of the datasets and the databases, where these are
accessible. Data filtering and pre-processing is explained in
Supplementary File S1.
Signature score calculation. Expression data of the genes in
a signature was extracted from the dataset. The following step was
used to calculate a signature score for each patient included in the
dataset. This score was defined as the average expression value of
the genes in the signature (equation (1)). When a gene was
represented by more than one reporter on an array, the expression
of the reporters was averaged before signature calculation. The
signature scores for each patient were then coupled to the survival
data of the patients.
Score~
X N
i~1
expi,m
N
ð1Þ
Where: Score, signature score; N, number of genes in the
signature; expi,m, gene expression of gene i in sample m.
The signature score was used to median dichotomize the patient
cohorts.
In a second setup expression of the genes in the signature were
used for K-nearest neighbor classification (KNN) combined with
leave-one-out-cross validation (LOOCV). With this method one
patient is withheld and the class membership of this patient is
predicted using the KNN model (knnclassify function in Matlab)
built on the remaining patients. The event parameter of the
survival data was used as training class. This procedure was
repeated for each patient, resulting in a class prediction for the
whole cohort.
Analysis
The signature scores, median dichotomized groups or KNN
classifications were evaluated with the area under the curve (AUC)
of the receiver operator curve (ROC). Definitions for AUC
calculations are as follows:
– True positive: patient in the high score group that died from
disease
– False positive: patient in the high score group that is alive
– True negative: patient in the low score group that is alive
– False negative: patient in the low score group that died from
disease
A signature score was considered prognostic when the AUC is
#0.4 or $0.6. This cut-off value was based on the AUCs of
several published gene signatures evaluated in the study of Ntzani
et al. [26] (further details are given in the results section and
Supplementary File S1).
Supporting Information
Figure S1 Effect of number of genes, number of probes
per gene, filtering and signature evaluation procedure
on AUC distribution. A: Percentages of signatures that pass the
criteria of AUC#0.4 or AUC$0.6 for the 5 batches of 10,000
runs for the Miller dataset, groups consisting of half of the
UnigeneIDs of the Miller dataset. B: Percentages of signatures that
pass the criteria of AUC#0.4 or AUC$0.6 for the 5 batches of
10,000 runs for the Miller dataset, taking only one or multiple
reporters per gene into account. C: Percentages of signatures that
pass the criteria of AUC#0.4 or AUC$0.6 for the 5 batches of
10,000 runs for the Miller dataset, taking two different filtering
methods. D: Percentages of signatures that pass the criteria of
AUC#0.4 or AUC$0.6 for the 5 batches of 10,000 runs for the
Miller dataset, taking three different signature evaluation proce-
dures (KNN LOOCV: K-nearest neighbor classification with
leave-one-out cross validation).
(TIF)
Figure S2 Evaluating random gene sets in multiple
datasets. Percentages of signatures that pass the criteria of
AUC#0.4 or AUC$0.6 for the 5 batches of 10,000 runs for the
van de Vijver and Beer datasets separately and combined.
(TIF)
Figure S3 Kaplan-Meier survival analysis of 4 pub-
lished gene signatures. Kaplan-Meier survival curves for the
Miller dataset for 4 published signatures (A: Wound signature, B:
IGS, C: early hypoxia 0% and D: early hypoxia 2%).
(TIF)
File S1 The supplementary material contains a section with
supplementary materials and methods and a section supple-
mentary results. The supplementary materials and methods is a
more detailed description of the data analyses. The supplemen-
tary results describe the analyses to check the influence of
several parameters on the random signature AUC distribution
that had minimal to no effect. Further additional tables are
included.
(DOC)
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